Cardiomyopathy Clinical Trials

None

GENETICS MECHANISMS AND CLINICAL PHENOTYPES OF ARRHYTHMOGENIC CARDIOMYOPATHY

The well-established, consistent and precise phenotyping developed in the previous ARVC Registry (and published as the Modified Task Force Criteria), with a comprehensive primary genotyping approach, search for genetic modifiers, and biomarker analysis will fulfill the long-term goals of this proposal to identify the genetic basis of all forms of …

Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).

APOLLO-B: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

TBD

A Randomized Double Blind Placebo Controlled Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

20.0

A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Please see section 1 of the full protocol

Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy (PAPS): A Pilot Study

TBD

A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

This is a multicenter study to evaluate the long-term safety and tolerability of mavacamten in participants with nHCM who completed MAVERICK-HCM through Week 24 and enroll into this study within 3 months. All participants will receive active study drug as described below, but their status (active or placebo) in the …

Medtronic Evaluation of Multi-Electrode Phased RF Technology in Persistent Atrial Fibrillation

The Phased RF System includes the GENius Multi Channel Radio Frequency Ablation Generator and three anatomically designed, multi-electrode catheters: Pulmonary Vein Ablation Catheter GOLD (PVAC GOLD) Multi-Array Septal Catheter (MASC) Multi-Array Ablation Catheter (MAAC) INCLUSION CRITERIA History of symptomatic persistent or long-standing persistent atrial fibrillation defined as: o Persistent AF: …